Abstract:Glioblastoma (GBM) is a highly malignant, invasive, and poorly prognosed brain tumor. Unfortunately, active comprehensive treatment does not significantly prolong patient survival. With the deepening of research, it has been found that gut microbiota plays a certain role in GBM, and can directly or indirectly affect the efficacy of immune checkpoint inhibitors (ICIs) in various ways. (1) The metabolites produced by gut microbiota directly affect the host's immune homeostasis, and these metabolites can affect the function and distribution of immune cells, promote or inhibit inflammatory responses, affect the phenotype, angiogenesis, inflammatory response, and immune cell infiltration of GBM cells, thereby affecting the effectiveness of ICIs. (2) Some members of the gut microbiota may reverse T cell function inhibition, increase T cell anti-tumor activity, and ultimately improve the efficacy of ICIs by targeting specific immunosuppressive metabolites and cytokines. (3) Some members of the gut microbiota directly participate in the metabolic process of drugs, which can degrade, transform, or produce metabolites, affecting the effective concentration and bioavailability of drugs. Optimizing the structure of the gut microbiota may help improve the efficacy of ICIs. (4) The gut microbiota can also regulate immune cell function and inflammatory status in the brain through gut brain axis communication, indirectly affecting the progression of GBM and the therapeutic response to ICIs. (5) Given the importance of gut microbiota for ICI therapy, researchers have begun exploring the use of fecal microbiota transplantation (FMT) to transplant healthy or optimized gut microbiota to GBM patients, in order to improve their immune status and enhance their response to ICI therapy. Preliminary studies suggest that FMT may enhance the efficacy of ICI therapy in some patients. In summary, gut microbiota plays a crucial role in regulating ICIs in GBM, and with a deeper understanding of the relationship between gut microbiota and tumor immunity, it is expected to develop more precise and effective personalized ICI therapy strategies for GBM, in order to improve patient prognosis.

Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma

Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies

Gut microbiome modulates efficacy of immune checkpoint inhibitors

The role of the gut microbiota in tumor, immunity, and immunotherapy

Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment

Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)

Gut Microbiota in Brain Tumors: an Emerging Crucial Player.

Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors

Gut microbiome affects the response to immunotherapy in non-small cell lung cancer

Gut microbiota-mediated immunomodulation in tumor

Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?

The Role of Gut Microbiota in Tumor Immunotherapy

Gut Microbiota: A Double-Edged Sword in Immune Checkpoint Blockade Immunotherapy Against Tumors

Targeting gut microbiota for immunotherapy of diseases

Metabolic regulation on the immune environment of glioma through gut microbiota

Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes

Csig-21. The Role Of Gut Microbiota In Glioblastoma: Insights From Microbiome-Gene Expression Interactions

Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer

Gut Microbiome in Modulating Immune Checkpoint Inhibitors.

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies